Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia: a Double-blind Placebo-controlled Randomized Multicenter Study: The "SwissHandSpasm" Study

NCT03977493 is registered in ClinicalTrials.gov with Alain Kaelin as lead sponsor.

NCT NCT03977493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03977493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia: a Double-blind Placebo-controlled Randomized Multicenter Study: The "SwissHandSpasm" Study
Lead sponsor
Alain Kaelin
Phase
Phase 3
Overall status
Recruiting
Start date
February 21, 2018
Completion date
December 31, 2027
Enrollment
48 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

focal hand dystonia